RICHMAP
RICHMAP · Stock · NEW YORK STOCK EXCHANGE, INC. ← Markets

MCK · NEW YORK STOCK EXCHANGE, INC.

McKesson Corp

Health Care
$907.99
▼ 13.39 (1.45%)
Finnhub · 26. 9. 5. 오전 5:00 기준 (실시간~15분 지연)
GLOBAL MARKET WIRE MCK

McKesson Corp를 보는 글로벌 시선

이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님

LOAD
CALL TRACKER검증 전체 →
차트 TradingView

재무 요약

Finnhub /stock/metric · 연간 기준 · 캐시 6h
PER (연간)
22.56
EPS (연간)
38.37
매출/주 (연간)
3250.85
총이익률 (연간)
3.60%
영업이익률 (연간)
1.54%
순이익률 (연간)
데이터 없음
ROE
17.67%
배당수익률
0.54%
52주 최고
999
52주 최저
682.35
시총 (M)
105,863 USDM
상장 주식수 (M)
117.08

▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)

관련 뉴스

Finnhub /company-news · 최근 14일 · 캐시 30min
Yahoo · 2026. 9. 5.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 5.

Why Is McKesson (MCK) Up 5.7% Since Last Earnings Report?

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 4.

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson has outpaced the healthcare sector, and analysts remain highly optimistic about the stock’s outlook.

원문 보기 ↗ Yahoo
Benzinga · 2026. 9. 4.

A Congress Member Sold Up To $15K In Viasat Stock: Here's What You Need To Know

A September filing shows that Representative Jonathan Jackson reported a sale in Viasat (NASDAQ:VSAT), valued between $1,001 and $15,000. The transaction date is listed as August 28, 2026, with the re…

원문 보기 ↗ Benzinga
Yahoo · 2026. 9. 4.

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-m…

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 4.

Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen

Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 3.

Is Generics Still a Quiet Profit Engine for Cardinal Health?

Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 2.

McKesson confirms data theft in cyberattack involving third-party apps

The healthcare distributor said the incident affected a subset of customers in its oncology and medical-surgical businesses.

원문 보기 ↗ Yahoo
Yahoo · 2026. 9. 1.

Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

원문 보기 ↗ Yahoo
Yahoo · 2026. 8. 30.

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

원문 보기 ↗ Yahoo
Yahoo · 2026. 8. 30.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

원문 보기 ↗ Yahoo
Yahoo · 2026. 8. 29.

McKesson Corporation (MCK) Doubles Down on Healthcare Growth With Precision Medicine Acquisition

McKesson Corporation (NYSE:MCK) has agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion, as the healthcare company continues shifting its portfolio toward higher-…

원문 보기 ↗ Yahoo
⚡ WHAT-IF ARENA · SIMULATION · 가상 · 실제 거래 아님

내 성향 트레이더로 도전

주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.

⚠ 정보 제공 목적 · 투자 추천·자문 아님

본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.